Introduction {#S1}
============

Squamous cell carcinoma (SCC) causes \>900,000 deaths worldwide and arises in stratifying epithelial tissues such as skin, lung, esophagus and cervix. Common mutation profiles and perturbed signaling events have been identified in SCC arising in different tissues, including loss of function *NOTCH1* mutation in skin, lung and esophagus ([@R11]; [@R44]; [@R1]; [@R14]; [@R50]). Squamous cell carcinoma of the skin (cutaneous SCC, cSCC) is an increasing health problem with up to an estimated 400,000 new cases diagnosed in 2012 in the US and characterized by an upward trend with an increase of up to 200% over the past three decades ([@R21]). In Scotland cSCC is the fourth most frequent cancer registration behind basal cell carcinoma of the skin, lung and bronchus, and breast (ISD Scotland 2010 data: <http://www.isdscotland.org/Health-Topics/Cancer/>). Although it contributes only 0.37% overall cancer mortality, compared with 26% lung and bronchus and 7% breast (ISD Scotland), locoregional and metastatic cSCC has a dismal prognosis, with reported five year survival rates below 30% ([@R23]; [@R7]). Indeed, since tumors are visible from the outset, it is timely intervention, rather than tumor factors per se, which probably contributes to the relatively low mortality rate ([@R49]). In high risk populations, such as immune-suppressed organ transplant recipients, cSCC is both 100-fold more frequent and shows increased mortality ([@R39]; [@R15]). Cutaneous side effects, particularly cSCC are commonly observed in patients receiving a range of targeted cancer therapies demonstrating that perturbation of signaling pathways which drive cancer progression frequently disrupt homeostasis in the skin ([@R4]). Of note, patients receiving BRAF or broad spectrum kinase inhibitors frequently manifest squamoproliferative lesions and cSCC ([@R2]). Previous reports have identified key driver mutations (known as Mut-driver genes) in *TP53* ([@R6]; [@R33]), *NOTCH* receptors ([@R11]; [@R50]) and *RAS* ([@R34]; [@R8]) in sporadic cSCC and more recently a significant contribution of *RAS* mutations to kinase inhibitor-driven cSCC ([@R45]). In order to define and assess the contribution of Mut-driver genes to a large number of sporadic cSCC and then compare this with kinase inhibitor induced cSCC and squamoproliferative lesions we have used exome capture and Illumina technology to sequence 20 sporadic cSCC followed by a targeted PCR amplification approach coupled with Roche 454 sequencing in a further 151 samples; 91 sporadic cSCC, 21 cSCC cell lines and 39 cSCC and squamoproliferative lesions isolated from patients receiving the BRAF inhibitor vemurafenib. In addition we sequenced 10 normal skin samples, 4 using exome capture and 6 using PCR amplification.

Results {#S2}
=======

Cutaneous SCC harbors a massive burden of mutation compared with common malignant tumor types {#S3}
---------------------------------------------------------------------------------------------

Whole exome sequencing of 20 cSCC stratified by histological grade along with matched germline DNA ([Supplementary Data Table 1](#SD2){ref-type="supplementary-material"}) targeted 351,845 exons from 21,117 genes. The mean sequencing coverage across targeted bases was 64X, with 69% above 30X coverage. We identified a total of 20,671 non-silent (non-synonymous) mutations (mean of 1,034 and a median of 1,195 per tumor) with a mean total exonic mutations per tumor of 2,283 corresponding to a mean somatic mutation rate of 50 mutations per mega-base pair (Mbp) of DNA ([Figure 1](#F1){ref-type="fig"}, [Supplementary Data Table 2](#SD2){ref-type="supplementary-material"}). The prevalent nucleotide change was C\>T, 68% of all somatic mutations, consistent with UV damage. Frequency of mutation in known drivers of cSCC was consistent with previous studies ([Figure 1](#F1){ref-type="fig"}). The burden of mutation we describe here is significantly greater than any other common malignant tumor type, with the exception of basal cell carcinomas (5 fold greater than lung cancer ([@R14]) for example; ([Supplementary Data Figure 1A](#SD1){ref-type="supplementary-material"}) and comparable to tumors with microsatellite instability (MSI) characterized by hypermutation and disruption of genes encoding DNA excision repair proteins and/or the DNA polymerase subunit POLE ([@R47]; [@R20]). Unlike tumors with MSI, cSCC mutation burden showed no discernible segregation with mutations in DNA excision repair pathway genes or the DNA polymerase subunit POLE ([Supplementary Data Figure 1B](#SD1){ref-type="supplementary-material"}). Basal cell carcinoma of the skin, with limited metastatic potential, harbors a 1.5 fold higher mutation rate ([@R18]) than the cSCC we describe here suggesting that in vivo, epidermal keratinocytes require multiple mutations for transformation to occur.

We identified non-synonymous mutations in 68 genes in 40% or more of the discovery exome cohort ([Supplementary Data Figure 2A](#SD1){ref-type="supplementary-material"}) of which a significant proportion (72%) had larger open reading frames than *NOTCH1* ([Supplementary Data Table 3](#SD2){ref-type="supplementary-material"}) making identification of new Mut-driver genes difficult. Indeed a large proportion of these genes were recently identified as likely passenger mutations from a meta-analysis of tumor exome and whole genome sequencing data ([@R24]). In this study later replication during S phase was identified as a factor increasing mutation by chance and of the 68 highly mutated genes described here, 62% have later replication timing than *NOTCH1* ([Supplementary Data Table 3](#SD2){ref-type="supplementary-material"}). In keeping with a high background mutation rate unsupervised hierarchical clustering failed to separate cSCC based on histological grade or mutation profiles ([Supplementary Data Figure 2B](#SD1){ref-type="supplementary-material"}).

NOTCH and RAS mutation segregate in sporadic cSCC and BRAF-inhibitor induced squamoproliferative lesions and cSCC {#S4}
-----------------------------------------------------------------------------------------------------------------

Next we pursued status of known, defined Mut-driver genes in a validation cohort of \>100 sporadic cSCC samples (91 fresh frozen cSCC and 21 cell lines derived from cSCC) and 39 skin lesions arising in 7 patients receiving vemurafenib ([Supplementary Data Table 4](#SD2){ref-type="supplementary-material"}). We used 454 pyrosequencing and Fluidigm amplicon library preparation to re-sequence *NOTCH1*, *NOTCH2*, *TP53*, *CDKN2A*, *HRAS*, *KRAS* and *NRAS* ([Figure 2A](#F2){ref-type="fig"}; [Supplementary Data Tables 5](#SD2){ref-type="supplementary-material"}-[11](#SD2){ref-type="supplementary-material"}). In total we sequenced 111 amplicons in 157 samples generating a mean sequencing coverage of 49X over 95 targeted exons. Using this approach we identified a similar mutation frequency in cSCC Mut-driver genes between the exome and 454 cohort of fresh frozen sporadic cSCC samples (n=91) with overall *NOTCH1* and *NOTCH2* combined mutation frequencies of 82%, *TP53* 63%, *CDKN2A* 28% and activating mutations in *RAS* at 11%. The increase in frequency of *NOTCH1* mutation in the 454 data (75% compared with 45% in the exome study) is attributed to an overall low coverage for the exome capture sequencing of this gene ([Figure 3A](#F3){ref-type="fig"}). This observation explains the higher proportion of non-sense mutations in *NOTCH1* comparing exome capture to 454 sequencing as, interestingly, allelic frequency of non-sense mutations was nearly double that of missense mutation in the 454 cohort ([Figure 3B](#F3){ref-type="fig"}). 21 primary cultures derived from cSCC tumors were also screened with the 454 platform and gave comparable mutation frequencies to tumor tissue with the exception of an increase in *CDKN2A* mutation, consistent with loss in culture ([@R27]) ([Figure 2B](#F2){ref-type="fig"}). Sequenced DNA of 39 squamoproliferative lesions or cSCC excised from 7 patients receiving the BRAF inhibitor vemurafenib showed a significant difference in overall mutation frequency (p\<0.05) with the exception of *KRAS* and *NRAS*. Activating *HRAS* mutations, known to be frequent in such lesions ([@R45]) were increased (38% versus 5%) while *NOTCH1* mutations, although less frequent than sporadic cSCC (49% versus 75%), were greater still (49% *NOTCH1* versus 38% *HRAS*) suggesting *NOTCH1* mutation is required for vemurafenib driven keratinocyte clonal expansion ([Figure 2C](#F2){ref-type="fig"}). Of the 16 samples harboring activating RAS mutations, 56% (9) also harbored a mutation in *NOTCH1* or *NOTCH2*. In the sporadic cSCC cohort this figure was 100% (8/8). 97% of variants detected by exome capture and Illumina sequencing in the discovery cohort of 20 cSCC were confirmed using 454 pyrosequencing (data not shown).

NOTCH receptor and activating HRAS mutation identified in normal skin {#S5}
---------------------------------------------------------------------

Prevalent *NOTCH* and *HRAS* mutation identified in skin lesions rapidly promoted by BRAF inhibition suggests selection and expansion of pre-existing clonal populations harboring such mutation. Certainly experimental evidence suggesting that BRAF inhibition accelerates growth of cells harboring activating RAS mutation supports this notion ([@R16]; [@R35]). We analysed *NOTCH*, *TP53*, *CDKN2A* and *RAS* mutation status in 10 normal skin samples. Four were used as control DNA for the exome sequencing as peripheral blood was not available for these patients (Materials and Methods; [Supplementary Data Table 1](#SD2){ref-type="supplementary-material"}) and 6 samples were obtained from patients receiving vemurafenib and were analysed by 454 sequencing ([Supplementary Data Table 4](#SD2){ref-type="supplementary-material"}).

In the exome sequenced samples we observed a *HRAS* G12D mutation and a single base pair deletion causing a frameshift in *NOTCH1* in normal skin from patient PD_05, both of which met criteria used to call somatic mutations in the tumor samples (Materials and Methods). This normal skin sample was isolated from a site distant to the tumor ([Supplementary Data Table 1](#SD2){ref-type="supplementary-material"}) and neither of these mutations were present in the tumor sample or were found in public databases (Materials and Methods) or, in the case of the NOTCH1 deletion, in any other samples sequenced during this study. In the absence of peripheral blood or any other source of germ line DNA we cannot completely rule out that these are somatic mutations, however, we find the possibility of an activating *HRAS* or loss of function *NOTCH1* present in the germline unlikely. Further interrogation of *NOTCH*, *TP53*, *CDKN2A* and *RAS* genes in the exome skin samples using IGV ([@R48]) revealed two non-sense *NOTCH1* mutations in PD_02 and PD_05 samples (E1270\* and E124\*) at frequencies or coverage below the detection criteria (2 from 10 reads and 5 from 12 reads respectively). A number of low frequency variants leading to activating mutations in all three RAS genes were observed across all four normal skin samples analysed with exome sequencing but only HRAS G12V in PD_08 was present in more than a single read albeit at a very low frequency (2 from 83 reads).

454 sequencing of 6 normal skin samples from patients receiving vemurafenib identified 5 *NOTCH1* mutations and one *NOTCH2* mutation which met the 454 detection criteria ([Supplementary Data Tables 8](#SD2){ref-type="supplementary-material"} and [9](#SD2){ref-type="supplementary-material"}; [Figure 2C](#F2){ref-type="fig"}). Of these, a single *NOTCH1* mutation was present at low allelic frequency in the skin adjacent to an SCC which harbored the identical mutation at considerably higher allelic frequency (14% vs 37%, [Supplementary Data Table 8](#SD2){ref-type="supplementary-material"}). Although an additional source of germ line DNA was not available to confirm whether these mutations were somatic or not, the low allelic frequency in normal skin and the fact that none of these mutations, other than the one found in the adjacent SCC were present in any of the other samples from the same patient strongly suggests that they are indeed somatic.

Vemurafenib induced squamoproliferative lesions and cSCC reveal surprising heterogeneity and independent activating HRAS mutations within the same lesion {#S6}
---------------------------------------------------------------------------------------------------------------------------------------------------------

In order to assess heterogeneity of skin lesions arising in vemurafenib treated patients we isolated DNA from two separate halves of 8 samples and performed 454 sequencing as before. In some instances coverage at RAS loci was low and so we reduced the detection threshold for activating RAS mutations to 2 or more reads over 10% of total reads. Bisected vemurafenib induced lesions revealed surprising heterogeneity, with the same mutation being identified in only 4 of the 8 separate lesion halves. All shared mutations were in *HRAS* with no shared mutations observed in *NOTCH1* or *TP53*. In one of the 8 samples different activating *HRAS* mutations were identified in the two separate halves of the same cSCC ([Figure 4](#F4){ref-type="fig"} and [Supplementary Data Table 12](#SD2){ref-type="supplementary-material"}).

Activated NOTCH1 detected by immunohistochemistry correlates with mutation status in cSCC and readily identifies regions of normal skin negative for NOTCH1 signaling {#S7}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Next we utilized a recently developed immunohistochemical (IHC) stain using an antibody which detects a neoepitope created by the proteolytic cleavage event that activates NOTCH1 ([@R22]). In total we analyzed 56 FFPE blocks from 36 cSCC samples for which we had mutation analysis (summarized in [Figure 5A](#F5){ref-type="fig"}). Immunoblotting total cell lysates isolated from cSCC cell lines with defined mutations demonstrated the specificity of the antibody ([Figure 5B](#F5){ref-type="fig"}). We observed positive nuclear NOTCH1 immuno-reactivity in all 6 cSCC samples where no mutations were identified ([Figure 5C](#F5){ref-type="fig"}). In the only sample where non-sense mutation was identified at an allelic frequency of 100% we saw no IHC staining ([Figure 5D](#F5){ref-type="fig"}). In cSCC samples where mutations in *NOTCH1* were at heterozygous or subclonal allelic frequencies we frequently observed regions of weak staining ([Figure 5E](#F5){ref-type="fig"}, left panel) as well regions of absent staining ([Figure 5E](#F5){ref-type="fig"}, right panel). Finally we analyzed normal looking skin at the periphery of cSCC and readily detected patches with no or very weak IHC staining flanked by normal looking IHC staining ([Figure 5F](#F5){ref-type="fig"}).

Discussion {#S8}
==========

Here we present exome level sequencing of a discovery set of 20 cSCC and validation by targeted deep sequencing of *NOTCH1*, *NOTCH2*, *TP53*, *CDKN2A* and *RAS* in over 150 cSCC and squamoproliferative lesions as well as 10 matched normal skin samples. Our initial discovery series identifies a massive burden of mutation far exceeding that of any other commonly registered cancer with metastatic potential sequenced to date; 5 fold greater than lung cancer, and an order of magnitude greater than breast ([@R14]; [@R43]). The mutation rate of 50 per Mbp is in line with an earlier study of 8 cSCC which identified a mean mutation rate of 33 per Mbp ([@R11]). Even compared to a subset of colorectal cancers with MSI ([@R47]), cSCC tumors harbor a greater median number of non-synonymous mutations ([Supplementary Data Figure 1A](#SD1){ref-type="supplementary-material"}). MSI tumors are associated with a high base pair substitution rate, low copy number variation and low TP53 mutation ([@R5]; [@R41]). Mutation and epigenetic silencing of DNA excision repair pathway genes and hotspot mutations in the DNA polymerase subunit POLE have recently been shown to be prevalent in highly mutated colorectal and endometrial carcinomas ([@R47]; [@R20]). In contrast, cSCC exhibit high copy number variation ([@R3]; [@R37]), TP53 mutation ([@R10]) and low frequency of DNA repair/ polymerase mutation ([Supplementary Data Figure 2B](#SD1){ref-type="supplementary-material"} and ([@R31])). Although we have not explored the possibility that methylation acts as a mechanism of silencing the expression of the mismatch repair (MMR) genes MLH1 or MSH2, (commonly identified in MSI ([@R20])), a recent study of 86 cSCC identified protein expression in all tumors indicating competent MMR ([@R31]). The high rate of C\>T transitions (68%) confirms UV radiation as the primary cause of cSCC mutation ([@R6]). Our data identifying *TP53* mutation in all but one of the heavily mutated tumors ([Figure 1A](#F1){ref-type="fig"}) would agree with a loss of wild type *TP53* preceding massive expansion of mutation as reported previously ([@R11]). The high mutation rate coupled with a similar burden identified in the most common tumor of the skin, basal cell carcinoma ([@R18]), suggests that either epidermal keratinocytes are inherently resistant to transformation or that skin acts as a potent tumor suppressor keeping clonal expansion of tumor initiating cells at bay. Previous studies identifying only one or two oncogenes required for efficient transformation of primary human keratinocytes ([@R13]; [@R25]) would argue the latter and recent data implicating an altered dermal microenvironment driving cSCC arising in patients with the genetic blistering disease Recessive Dystrophic Epidermolysis Bullosa would also agree with this line of reasoning ([@R29]). In addition to these two independent observations the fact that perturbation of major signaling pathways, such as MAPK, leads to rapid clonal expansion of mutated keratinocytes in the skin would also point to the tumor suppressive properties of normal homeostatic human skin.

Our study confirms NOTCH receptor mutation as a major tumor suppressor mechanism in cSCC ([@R50]), giving an overall frequency in 112 tumor samples of 82% (in 91 fresh frozen cSCC and 21 cell lines analyzed by 454 sequencing), and identifies *NOTCH1* as a tumor suppressor important for HRAS driven skin carcinogenesis, being the only other Mut-driver gene identified in this study as being highly mutated in lesions arising in patients taking the BRAF inhibitor vemurafenib ([Figure 2](#F2){ref-type="fig"}). It is important to note that we cannot rule out other mutation events in genes not included in our targeted sequencing and that a comprehensive analysis through exome or whole genome sequencing would be of great value in understanding the mutation landscape of these lesions. Interestingly, activating *RAS* mutations co-segregated with *NOTCH1* mutation in the 454 cohort of 112 cSCC ([Figure 2](#F2){ref-type="fig"}). Overall activated RAS mutation frequency in this cohort was 11% in agreement with recent studies in similarly sized sample sets ([@R30]). Loss of NOTCH signaling in concert with recombinant oncogenic RAS has previously been shown to promote tumor development of normal human primary keratinocytes inoculated into immune compromised mice ([@R26]). Here we provide convincing evidence that this indeed is evident in vivo.

Field cancerization is a concept introduced by Slaughter and colleagues in 1953 to describe the observation that multiple primary SCC arise within close proximity suggestive of a predisposing area of tissue, or field ([@R40]). Molecular evidence to support this notion followed in the late 1990s primarily concentrating on TP53 mutation ([@R12]) but also describing unique epigenetic phenomena ([@R46]). Certainly in the skin field cancerization characterized by TP53 mutation has been well described ([@R19]; [@R42]). In our study we were unable to find any evidence of TP53 mutation in the 10 normal skin samples but readily identified *NOTCH* receptor mutation (70%) of which a proportion (2/7) were frameshift or PTC mutations. In support of this molecular data, IHC analysis revealed regions of normal looking skin with loss or severely reduced NOTCH1 signaling ([Figure 5F](#F5){ref-type="fig"}). Recent data show that in murine models inhibition of NOTCH signaling in the dermal compartment can induce spontaneous carcinogenesis ([@R17]) and that mosaic loss of NOTCH1 in the epidermal compartment can induce spontaneous tumors competent in NOTCH1 signaling ([@R9]). Collectively and considering the high frequency of NOTCH receptor mutation identified here we would consider NOTCH mutation as an early event in skin carcinogenesis similar to APC loss in the colon ([@R36]).

Lastly, although our exome sequencing failed to identify further definitive Mut-driver genes in cSCC (largely due to the heavily mutated nature of the tumor and the small sample size in the initial exome capture cohort) we note that within the 68 genes mutated in 40% or more samples *FAT1* and *CACNA1C* were second only to *NOTCH1* in the number of tumors harboring non-sense mutations (5 and 6 compared with 7). *FAT1* was recently identified in a transposon based tumor suppressor screen in cSCC ([@R38]) and as a novel Mut-driver gene in HNSCC ([@R28]; [@R32]).

In conclusion, we present a comprehensive mutation analysis of *NOTCH1*, *NOTCH2*, *TP53*, *CDKN2A* and *RAS* in over 170 cSCC, squamoproliferative lesions and normal skin samples demonstrating that NOTCH receptors are significantly mutated; 82% of sporadic cSCC (n=112); 49% of squamoproliferative lesions arising in patients receiving vemurafenib (n=39) and 70% of normal skin samples (n=10, 4 peri-lesional and 6 separate from lesion). Although clearly a larger study is required, we do show in one instance that normal skin adjacent to cSCC can harbor the same *NOTCH1* mutation at significantly lower allelic frequency suggesting that field effect can be driven by *NOTCH* mutation in a clinical setting. We also demonstrate oncogenic *HRAS* mutations are present in normal human skin, again albeit in a single sample. Overall these data attest to the tumor suppressive qualities of normal human skin and that perturbation of major signaling pathways in this tissue can lead to rapid expansion of pre-existing tumor initiating clonal populations, highlighting *NOTCH1* mutation as a gatekeeper event in squamous carcinogenesis of the skin.

Materials & Methods {#S9}
===================

Samples {#S10}
-------

Ethical approval for this investigation was obtained from the East London and City Health Authority local ethics committee and the study was conducted according to the Declaration of Helsinki Principles. All patients participating in this study provided written, informed consent. Punch biopsies of cSCC tissue were taken after surgical excision of tumors and immediately snap-frozen in liquid nitrogen with the remainder of the tumor sent for formalin fixation and histopathologic diagnosis. In order to enrich for tumor cell populations, fresh frozen cSCC biopsies were laser capture microdissected using the Zeiss Palm Microbeam microscope (Zeiss, UK). Depending on sample size and tumor purity as estimated from a reference H&E slide, between 30-60 sections of 8 μm thickness were cut onto 1.0 mm PEN membrane slides (Zeiss, UK), stained in 0.05% acid fuchsin (Acros Organics, NJ) in distilled water and 0.05% toluidine blue O (Acros Organics, NJ) in 70% ethanol and microdissected, with tumor cells collected into 180 μl ATL buffer (Qiagen, Crawley, UK). DNA extraction was performed using the QIAamp DNA micro kit (Qiagen, Crawley, UK) according to manufacturer's instructions. To provide a source of germline DNA, paired venous blood samples or normal skin were obtained concomitantly with cSCC tissue and stored at −80 prior to DNA extraction using the protocol above in the case of normal skin or the QIAamp DNA blood mini kit (Qiagen, Crawley, UK). Squamoproliferative lesions included in this series were all benign keratinocyte hyperproliferative lesions with or without features suggestive of viral infection but with no evidence of dysplasia or invasive malignancy.

Sequencing, mapping and variant analysis {#S11}
----------------------------------------

Detailed methods are provided in the [supplementary data](#SD1){ref-type="supplementary-material"}. Briefly, exome capture and sequencing was provided by the EASIH - University of Cambridge supported by NIHR - Cambridge BRC using Agilent SureSelect Human All Exon 50 Mb according to the manufacturers' instructions, coupled with Illumina HiSeq technology. Exome capture variant detection required a minimum read depth at a position to make a call of 10, a minimum of 4 supporting reads and a minimum variant allele frequency threshold of 0.2. 454 pyrosequencing was performed using the GS Junior system (Roche/454 Life Sciences) and Fluidigm (Fluidigm Corporation, San Francisco, CA) PCR amplicon libraries as template according to recommended guidelines (Roche, Mannheim, Germany). 454 variant detection required a minimum of 4 supporting reads and a minimum variant allele frequency threshold of 0.1.

Statistics {#S12}
----------

Chi-Square test was used where permitted (*NOTCH1*, *NOTCH2*, *TP53*, and *HRAS*) and Fischer's exact test was used where numbers were too low (*CDKN2A*, *KRAS*, and *NRAS*) to determine whether mutation frequencies between sporadic cSCC (n=91) and vemurafenib induced lesions (n=39) significantly differed.
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![High mutation rate and spectra indicative of ultraviolet radiation damage in 20 sporadic cSCC samples\
Upper bar graph shows exonic mutations per megabase for each individual tumor. Middle bar graph shows the spectrum of individual tumor somatic mutations as a percentage. Lower matrix depicts mutations (indicated by a filled square) in each individual tumor in genes previously reported to be frequently mutated in cSCC. Where more than one mutation is present in a single gene only one mutation type is given in the order delineated by color coded key; activating-Ras, nonsense, frameshift, splice site, missense.](emss-57574-f0001){#F1}

![454 resequencing identifies prevalent mutation *NOTCH1*, *NOTCH2* and *TP53* in cSCC\
Upper Matrix depicts mutations in the given gene for each individual tumor sample. Where more than one mutation is present in a single gene two mutations are shown in the order delineated by key; activating RAS, frameshift, nonsense, splice site, missense. Lower left matrix details mutations in 21 keratinocyte cSCC cell lines and lower right matrix details mutations in 39 skin lesions excised from 7 patients receiving the BRAF inhibitor vemurafenib. Mutations identified in normal skin DNA isolated from 6 of these 7 patients are shown to the right of this matrix.](emss-57574-f0002){#F2}

![*NOTCH1* coverage is lower in exome capture compared with PCR amplification and 454 sequencing\
**A:** Percentage of the *NOTCH1* gene represented by 1X, 10X, 20X and 30X coverage in the first two samples sequenced using PCR amplification and 454 pyro-sequencing (454: TGM1 and 454: TGM2) compared with exome capture (Ex: WD_01 and Ex: WD_02).\
B: The mean allelic frequency of non-sense and missense mutations identified in *NOTCH1* from 91 cSCC fresh frozen samples. Error shows standard deviation. Student T-Test p-value = 7e-06.](emss-57574-f0003){#F3}

![Bisected vemurafenib induced squamoproliferative lesions and cSCC display significant heterogeneity\
Cartoons depict 8 bisected vemurafenib induced lesions and the resulting mutations identified in *NOTCH1*, *NOTCH2*, *HRAS* and *TP53* from the isolated DNA. Solid lines enclose mutations in HRAS shared by both halves of the sample whilst dashed lines enclose different mutations in the same gene identified in the two halves of the sample. % indicates allelic frequency.](emss-57574-f0004){#F4}

![NOTCH1 Western blotting and immunohistochemistry correlates with mutation status and identifies regions of normal looking skin negative for NOTCH1 signaling\
Standard 4-micron paraffin embedded tissue sections were stained using the Ventana Benchmark XT platform (Ventana Medical Systems, Inc., Tucson, AZ.) with extended heat induced epitope retrieval (CC1 Buffer). Slides were incubated for 1hr at room temperature with anti-NICD1 rabbit monoclonal antibody (clone D3B8, catalog \#4147, Cell Signaling Technology, Beverly, MA; final concentration, 8.5microgram/mL). Signals were then amplified (Ventana Amplification Kit, \#760-080) and visualized (Ventana Ultraview Universal DAB detection kit, \#760-500) per the manufacturer's instructions. **A:** Summary of immune-reactivity of 36 cSCC samples with anti-NICD1 antibody. **B:** Western blotting with 50μg of total cell lysate from SCCIC12 (no mutations), SCCT2 (missense, loss-of-function mutations) and SCCIC8 (homozygous PTC mutation) were resolved by 4-12% SDS-PAGE using standard techniques. The proteins were then transferred to a nitrocellulose membrane and visualized using antibodies recognizing full length NOTCH1, NICD1 and GAPDH. **C:** Immunohistochemistry data from sample TGP8, no NOTCH1 mutations. **D:** Sample TGW29, 100% STOP mutation. **E:** Sample TGM4, P391S 55%, G4247D 22%, P1860L 37% mutations. Left panel shows weakly positive region of the tumor while right panel shows negative region of the same tumor. **F:** Normal looking peri-tumor skin showing regions negative for NOTCH1 signaling adjacent to regions displaying the expected normal distribution of activated NOTCH1. Right panel shows extent of NOTCH1 negative patch flanked by positive NOTCH1 skin. All bars **C-F** = 300μm.](emss-57574-f0005){#F5}
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